Valdmedika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 28,168 | 42,560 | 44,002 | 125,949 | 287,901 | 558,154 | 742,098 | 1,126,331 |
| Profit before tax | 4,984 | 698 | 2,744 | 53,566 | 12,846 | 29,006 | 71,628 | 46,949 |
| Net profit | 4,984 | 698 | 2,651 | 50,893 | 12,324 | 25,195 | 61,215 | 40,748 |
| Equity | 910 | 1,608 | 4,259 | 55,152 | 67,476 | 92,671 | 153,886 | 194,634 |
| Liabilities | 30,546 | 35,678 | 35,626 | 52,798 | 45,090 | 186,038 | 153,596 | 224,366 |
| Non-current assets | 21,922 | 20,741 | 18,881 | 15,847 | 33,476 | 59,984 | 75,754 | 145,684 |
| Current assets | 9,534 | 16,545 | 21,004 | 94,544 | 79,090 | 218,725 | 231,728 | 273,316 |
| Total assets | 31,456 | 37,286 | 39,885 | 110,391 | 112,566 | 278,709 | 307,482 | 419,000 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 44,662 | 76,471 | 173,562 |
| Social insurance contributions | - | - | - | - | - | 7,236 | 7,677 | 14,171 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +149.4% | +51.1% | +3.4% | +186.2% | +128.6% | +93.9% | +33.0% | +51.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 15.8% | 1.9% | 6.6% | 46.1% | 10.9% | 9.0% | 19.9% | 9.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 547.7% | 43.4% | 62.2% | 92.3% | 18.3% | 27.2% | 39.8% | 20.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 17.7% | 1.6% | 6.0% | 40.4% | 4.3% | 4.5% | 8.2% | 3.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 17.7% | 1.6% | 6.2% | 42.5% | 4.5% | 5.2% | 9.7% | 4.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 33.6 | 22.2 | 8.4 | 1.0 | 0.7 | 2.0 | 1.0 | 1.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 28,168 | 42,560 | 44,002 | 125,949 | 88,585 | 119,604 | 148,420 | 275,838 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Valdmedika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-11-16 | 2023-11-20 | 1.94 |
| 2023-10-25 | 2023-11-05 | 1.93 |
| 2023-08-17 | 2023-08-20 | 547.47 |
Valdmedika - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Valdmedika, UAB (code 304148483) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025, the company generated EUR 1.13 million in revenue, up 51.8% year on year and 101.8% over two years. Net profit reached EUR 40.7 thousand, compared with EUR 61.2 thousand in 2024 and EUR 25.2 thousand in 2023, showing strong growth in 2024 followed by a lower but still positive result in 2025. The 2025 profit margin was 3.6%, below the 8.2% achieved in 2024. At year-end 2025, total assets stood at EUR 419.0 thousand, equity at EUR 194.6 thousand, and liabilities at EUR 224.4 thousand. The equity ratio was 46.5% and debt-to-equity was 1.15. Asset turnover reached 2.69x, reflecting efficient use of assets relative to revenue. Profitability indicators for 2025 were solid, with ROE at 20.9% and ROA at 9.7%. Revenue per employee was EUR 281.6 thousand, while profit per employee was EUR 10.2 thousand, indicating relatively high productivity.